Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.40 Average PT from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.40.

STOK has been the topic of several recent research reports. Wedbush restated an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 11.30% of the stock is currently owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Birchview Capital LP lifted its holdings in shares of Stoke Therapeutics by 147.1% during the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after buying an additional 125,000 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Stoke Therapeutics in the first quarter valued at about $1,224,000. BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after purchasing an additional 6,636 shares during the last quarter. Chase Investment Counsel Corp purchased a new position in Stoke Therapeutics in the first quarter worth about $279,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $141,000.

Stoke Therapeutics Stock Down 1.5 %

STOK opened at $12.19 on Friday. The stock has a market cap of $635.35 million, a PE ratio of -5.06 and a beta of 0.96. The business has a 50 day moving average of $14.22 and a 200-day moving average of $13.47. Stoke Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. The firm had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. Equities analysts anticipate that Stoke Therapeutics will post -2.1 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.